Real-World Patient Experiences With Concomitant Ixekizumab and Tirzepatide in Psoriasis: Participants Recruited From the Zepbound® Savings for Taltz® US Customer Support Program

Introduction: Psoriasis (PsO) commonly co-occurs with obesity/overweight (OO) and shares immunometabolic pathways. Ixekizumab (IXE) is approved to treat PsO, and tirzepatide (TZP) is the only weight loss therapeutic studied in a controlled trial in concomitant use with IXE. In the TOGETHER-PsO trial, significantly more participants with PsO and OO treated with concomitant IXE and TZP simultaneously achieved complete skin clearance (Psoriasis Area and Severity Index 100) and ≥10% weight reduction at 36 weeks than participants treated with IXE alone. The current observational study assessed patient-reported treatment satisfaction, disease activity, quality of life (QoL), and weight reduction in participants with PsO and OO who were taking concomitant IXE and TZP in a real-world setting. Methods: Adults who had PsO and OO were recruited from the US customer support program, Zepbound® Savings for Taltz®. In this cohort, IXE was prescribed by healthcare providers in dermatology and TZP was prescribed by various healthcare providers. Participants completed a cross-sectional self-reported survey, which included the following patient-reported outcomes: Patient Reported Extent of Psoriasis Involvement (PREPI, including percent body surface area [%BSA]), Skinfold Psoriasis Assessment Form (bother Numeric Rating Scale [NRS]), Patient Global Assessment of Disease Activity for PsO (PtGA-PsO), Worst Itch NRS, Fatigue NRS, Dermatology Life Quality Index (DLQI), Patient Global Impression of Change (PGIC), and Patient Global Assessment of Treatment Satisfaction (PtGA-SAT; for IXE and TZP separately). Participants reported their weight before TZP, their current weight, and the number of pant (trouser) sizes reduced. Percentage of weight reduction was calculated between pre-TZP and current weight. Data were analyzed descriptively. Results: The survey included 89 participants with PsO (82.0% female; mean age, 46.3 years; 65.2% with psoriatic arthritis [PsA]). At the time of the survey, 76.4% had received IXE ≥6 months and 47.2% had received TZP for ≥6 months. Mean scores indicated mild PsO (%BSA: mean 1.7; standard deviation [SD] 5.4; range 0.0–50.0), mild bother from PsO (mean 1.6; SD 2.4; range 0.0–9.0), mild disease activity (PtGA-PsO: mean 1.0; SD 1.3; range 0.0–5.0), mild fatigue (Fatigue NRS: mean 2.3; SD 2.3; range 0.0–8.0), mild itch (Worst Itch NRS: mean 1.3; SD 1.8; range 0.0–8.0), and minimal disease impact on QoL (DLQI: mean 2.6; SD 4.6; range 0.0–26.0). Patient-perceived improvements (PGIC) in PsO/PsA and weight since starting TZP were reported by 65.2% of participants. TZP was mostly prescribed by primary care providers (62.9%) or dermatologists (21.3%). Regarding weight reduction since TZP, 25.8% of participants had achieved 0–5% reduction, 13.5% had achieved >5–10% reduction, and 60.7% had achieved >10% reduction; 77.5% had experienced ≥1 pant size reduction. Overall, 89.9% of participants reported satisfaction with both IXE and TZP. Conclusion: Across varying treatment durations, participants with PsO and OO reported high satisfaction with both IXE and TZP, alongside low disease activity, low QoL burden, and substantial weight reduction. These findings support the potential of concomitant IXE and TZP for patients with PsO and OO as part of a holistic treatment plan.